Iguvic 25 Tablet contains Iguratimod 25 mg as its active ingredient, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of rheumatoid arthritis. Iguratimod exerts anti-inflammatory and immunomodulatory effects by inhibiting the production of pro-inflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha, thereby reducing synovial inflammation and joint destruction. It also suppresses immunoglobulin synthesis and modulates immune cell function, contributing to its efficacy in controlling disease activity and preventing progression. Iguvic 25 is prescribed as part of a comprehensive management plan for patients with active rheumatoid arthritis who have an inadequate response to conventional therapy. The tablet is administered orally, typically once or twice daily, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include gastrointestinal disturbances, elevated liver enzymes, and mild hematological changes, necessitating regular monitoring of liver function tests and blood counts during therapy. Iguvic 25 should be used cautiously in patients with hepatic or renal impairment and is contraindicated in pregnancy and lactation due to potential risks to the fetus or infant. It is essential to follow the prescribing physician’s guidance and report any unusual symptoms promptly to ensure safe and effective treatment outcomes.